1. Home
  2. ZLAB

ZLAB

Zai Lab Limited

Logo Zai Lab Limited

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Founded: 2013 Country:
China
China
Employees: 2175 City: SHANGHAI
Market Cap: 1.4B IPO Year: 2017
Target Price: $64.22 AVG Volume (30 days): 688.9K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.50 EPS Growth: N/A
52 Week Low/High: $14.29 - $40.42 Next Earning Date: 05-07-2024
Revenue: $266,719,000 Revenue Growth: 24.03%
Revenue Growth (this year): 54.31% Revenue Growth (next year): 63.33%

Share on Social Networks: